Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer

被引：6

作者：

Sekine, I. ^{[1
]}

Nokihara, H. ^{[1
]}

Takeda, K. ^{[2
]}

Nishiwaki, Y. ^{[3
]}

Nakagawa, K. ^{[4
]}

Isobe, H. ^{[5
]}

Mori, K. ^{[6
]}

Matsui, K. ^{[7
]}

Saijo, N. ^{[3
]}

Tamura, T. ^{[1
]}

机构：

[1] Natl Canc Ctr, Div Internal Med & Thorac Oncol, Tokyo 1040045, Japan

[2] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan

[3] Natl Canc Ctr Hosp, Div Thorac Oncol, Kashiwa, Chiba, Japan

[4] Kinki Univ, Sch Med, Dept Med Oncol, Sayama, Osaka, Japan

[5] Natl Hosp Org Hokkaido Canc Ctr, Dept Pulm Dis, Sapporo, Hokkaido, Japan

[6] Tochigi Prefectural Canc Ctr, Utsunomiya, Tochigi, Japan

[7] Osaka Prefectural Med Ctr Respirat & Allergic Dis, Dept Internal Med, Habikino, Japan

来源：

BRITISH JOURNAL OF CANCER | 2008年 / 98卷 / 04期

关键词：

small-cell lung cancer; chemotherapy; irinotecan; etoposide; three drug combination;

D O I：

10.1038/sj.bjc.6604233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with previously untreated extensive-disease small-cell lung cancer were treated with irinotecan 60 mgm(-2) on days 1 and 8 and cisplatin 60 mgm(-2) on day 1 with (n = 55) or without (n = 54) etoposide 50 mgm(-2) on days 1-3 with granulocyte colony-stimulating factor support repeated every 3 weeks for four cycles. The triplet regimen was too toxic to be considered for further studies.

引用

页码：693 / 696

页数：4

共 50 条

[1] Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
I Sekine
H Nokihara
K Takeda
Y Nishiwaki
K Nakagawa
H Isobe
K Mori
K Matsui
N Saijo
T Tamura
British Journal of Cancer, 2008, 98 : 693 - 696
[2] Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
Noda, W
Nishiwaki, Y
Kawahara, M
Negoro, S
Sugiura, T
Yokoyama, A
Fukuoka, M
Mori, K
Watanabe, K
Tamura, T
Yamamoto, S
Saijo, N
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02): : 85 - 91
[3] Randomized phase II trial of irinotecan plus cisplatin (IP) versus irinotecan, cisplatin plus etoposide (IPE) every three weeks in patients with extensive disease small cell lung cancer (ED-SCLC).
Sekine, I.
Nokihara, H.
Takeda, K.
Nishiwaki, Y.
Nakagawa, K.
Isobe, H.
Mori, K.
Matsui, K.
Saijo, N.
Tamura, T.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 385S - 385S
[4] Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509
Satouchi, Miyako
Kotani, Yoshikazu
Shibata, Taro
Ando, Masahiko
Nakagawa, Kazuhiko
Yamamoto, Nobuyuki
Ichinose, Yukito
Ohe, Yuichiro
Nishio, Makoto
Hida, Toyoaki
Takeda, Koji
Kimura, Tatsuo
Minato, Koichi
Yokoyama, Akira
Atagi, Shinji
Fukuda, Haruhiko
Tamura, Tomohide
Saijo, Nagahiro
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1262 - +
[5] A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
Masahiro Tabata
Katsuyuki Kiura
Niro Okimoto
Yoshihiko Segawa
Tetsu Shinkai
Toshiro Yonei
Shoichi Kuyama
Shingo Harita
Katsuyuki Hotta
Hiroshi Ueoka
Mitsune Tanimoto
Cancer Chemotherapy and Pharmacology, 2007, 60 : 1 - 6
[6] A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
Tabata, Masahiro
Kiura, Katsuyuki
Okimoto, Niro
Segawa, Yoshihiko
Shinkai, Tetsu
Yonei, Toshiro
Kuyama, Shoichi
Harita, Shingo
Hotta, Katsuyuki
Ueoka, Hiroshi
Tanimoto, Mitsune
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 1 - 6
[7] Randomized Phase III Trail of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naive Korean Patients with Extensive-Disease Small Cell Lung Cancer
Kim, Dong-Wan
Kim, Hoon-Gu
Kim, Joo-Hang
Park, Keunchil
Kim, Hoon-Kyo
Jang, Joung Soon
Kim, Bong-Seog
Kang, Jin-Hyoung
Lee, Kyung Flee
Kim, Sang-We
Ryoo, Hun Mo
Kim, Jin-Soo
Lee, Ki Hyeong
Kwon, Jung Hye
Choi, Jin-Hyuk
Shin, Sang Won
Hahn, Seokyung
Heo, Dae Seog
CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 119 - 127
[8] Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer
Kim, Young Saing
Park, Se Hoon
Kyung, Sun Young
Sym, Sun Jin
Lee, Sang Pyo
Park, Jeong Woong
Jung, Sung Hwan
Park, Jinny
Cho, Eun Kyung
Lee, Jae Hoon
Shin, Dong Bok
MEDICAL ONCOLOGY, 2011, 28 (01) : 342 - 350
[9] Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer
Young Saing Kim
Se Hoon Park
Sun Young Kyung
Sun Jin Sym
Sang Pyo Lee
Jeong Woong Park
Sung Hwan Jung
Jinny Park
Eun Kyung Cho
Jae Hoon Lee
Dong Bok Shin
Medical Oncology, 2011, 28 : 342 - 350
[10] Irinotecan plus cisplatin in small-cell lung cancer
Sandler, A
ONCOLOGY-NEW YORK, 2002, 16 (09): : 39 - 43

← 1 2 3 4 5 →